In April this year, Saima Thompson was diagnosed with stage four non small cell lung cancer. She was 29-years-old. It was an horrific bolt from the blue and a testament to the indiscriminate brutality of this unforgiving disease. The young, successful business woman, owner of a vibrant Pakistani restaurant in south London, was suddenly staring down the barrel of a gun. Her life had been turned upside down.
So what on earth do you do in the face of such catastrophic news? Saima says that whatever her future held for her, she was determined to live.
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
